Bead Assisted Mass Spectrometry assay platform for targeted proteomics

Supported by:

15 April 2021

Supported by:

15 April 2021

Bruker Scientific webinar feature image


Bead Assisted Mass Spectrometry (BAMS™) is an assay platform that combines immuno-affinity capture on magnetic beads with detection by MALDI-TOF mass spectrometry for multiplexed, targeted proteomic assays. Almost any protein target is accessible as long as a specific affinity reagent (ie, antibody) is available.

The webinar focuses on the detailed description of the workflow and case studies of BAMS™ assays developed for targets relevant to neurology and virology. MALDI-TOF data resulted from the assays were discussed in depth.

Learning outcomes of this webinar:

  • Discover a novel, multiplexed, customisable assay platform for targeted proteomics and biomarker research
  • Understand how the BAMS™ assay platform can be used to characterise complex combinations of post-translational modifications (PTMs) and proteoforms of the protein target of interest
  • Learn from BAMS™ assay case studies relevant to neurology and virology.


Register to watch this on-demand webinar

    Unless making a secure payment with your credit or debit card via a third-party payment processor, this form is not designed to collect confidential or sensitive personal information (e.g., financial information, social security numbers).

    *Required field

    Your details

    Other information

    Email preferences

    If you’re not already opted-in to receive our emails, please select which types of communication you would like to receive:

    Confirm that you're human

    By clicking register, you consent to Drug Target Review contacting you about this and future webinars, and that you agree to our terms and conditions and privacy policy. Your information will be processed in accordance with GDPR and you can unsubscribe at any time.


    Sergei Dikler, PhD, Technical Project Manager

    Bruker webinar speaker imageDr Sergei Dikler received his PhD in Chemistry from the Texas A&M University under the direction of Professor David Russell. He joined Bruker Corporation and is currently a Technical Project Manager specialising in MALDI-TOF applications. Dikler has led or participated in product development projects such as the development of the MALDI PharmaPulse system, new method development for MALDI-TOF/TOF instruments including high-throughput screening, top-down and middle-down sequencing of intact proteins and many other projects. This work resulted in numerous conference presentations and publications in peer reviewed journals including a paper in Science that was published in 2018.

    Leave a Reply

    Your email address will not be published. Required fields are marked *